Glaxo’s Former China Head Accused of Ordering Bribes

Global Business

CCTV’s prime-time investigative program Jiaodian Fangtan reported that Chinese police handed a bribery case against GlaxoSmithKline Plc’s (GSK) China unit to prosecutors, accusing a British executive of ordering employees to illegally pay doctors, hospitals and medical associations to boost sales.

CCTV’s prime-time investigative program Jiaodian Fangtan reported that Chinese police handed a bribery case against GlaxoSmithKline Plc’s (GSK) China unit to prosecutors, accusing a British executive of ordering employees to illegally pay doctors, hospitals and medical associations to boost sales.

Glaxo’s Former China Head Accused of Ordering Bribes

Chinese police handed a bribery case against GlaxoSmithKline Plc’s (GSK) China unit to prosecutors, accusing a British executive of ordering employees to illegally pay doctors, hospitals and medical associations to boost sales.

Police had finished the investigation on the suspected bribery case of GlaxoSmithKline(GSK) China and handed it over to prosecutors, local police of Changsha, capital of central China’s Hunan Province, said in a statement.

William Mark Reilly, a British national and executive of GSK China, allegedly pressed his sales teams to bribe hospitals, doctors and health institutions through various means and gained an illegal revenue worth of billions.

He and two other executives, Zhang Guowei and Zhao Hongyan, were also suspected of bribing officials with the industry and commerce departments of Beijing and Shanghai.

The allegations are deeply concerning and contrary to the company’s values, Glaxo said in today’s statement, adding that it wants a resolution that will enable it to continue contributing to the welfare of China’s citizens. Glaxo said in December it was changing the way it compensates salespeople and would stop paying doctors for giving speeches and attending medical meetings.